Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2026 Jan;27(1):116-124.
doi: 10.1016/S1470-2045(25)00567-4. Epub 2025 Nov 20.

Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study

Collaborators, Affiliations
Observational Study

Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study

Natalia Alves et al. Lancet Oncol. 2026 Jan.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis among major cancer types, primarily due to late diagnosis on contrast-enhanced CT. Artificial intelligence (AI) can improve diagnostic performance, but robust benchmarks and reliable comparison to radiologists' performance are scarce. We established an open-source benchmark with the aim of investigating AI systems for PDAC detection on CT and compared them to radiologists' performance, at scale.

Methods: In this international, paired, non-inferiority, confirmatory, observational study (PANORAMA), the AI system was trained and externally validated within an international benchmark, with a cohort of 2310 patients from four tertiary care centres in the Netherlands and the USA for training (n=2224) and tuning (n=86), and a sequestered cohort of 1130 patients from five tertiary care centres (the Netherlands, Sweden, and Norway) for testing. A multi-reader, multi-case observer study with 68 radiologists (40 centres, 12 countries; median 9·0 [IQR 6·0-14·5] years of experience) was conducted on a subset of 391 patients from the testing cohort. The reference standard was established with histopathology and at least 3 years of clinical follow-up. The primary endpoint was the mean area under the receiver operating characteristic curve (AUROC) of the AI system compared to that of radiologists at PDAC detection on CT. The study protocol and statistical plan were prespecified to test non-inferiority (considering a margin of 0·05), followed by superiority towards the AI system. This study is registered with Zenodo (https://doi.org/10.5281/zenodo.10599559) and is complete.

Findings: Of the 3440 (1511 [44%] female, 1929 [56%] male; median age 67 [IQR 58-74] years) included patients (Jan 1, 2004 to Dec 31, 2023), 1103 (32%) received a positive PDAC diagnosis. In the sequestered testing cohort of 1130 patients (406 with histologically confirmed PDAC), AI achieved an AUROC of 0·92 (95% CI 0·90-0·93). In the subset of 391 patients (144 [37%] with histologically confirmed PDAC) used for the reader study, AI achieved statistically non-inferior (p<0·0001) and superior (p=0·001) performance with an AUROC of 0·92 (95% CI 0·89-0·94), compared to the pool of 68 participating radiologists, with an AUROC of 0·88 (0·85-0·91).

Interpretation: AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes.

Funding: European Union's Horizon 2020 research and innovation programme.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests NA has received funding from Siemens Healthineers and Johnson & Johnson. AS has received lecture honorarium on AI-assisted prostate cancer diagnosis from Guerbet. AK has received research funding from GE Healthcare and the Pancreatic Cancer Association network. J-ML has received consulting fees from Dr. Falk Pharma and Nordmark Pharma; honoraria from Abbott, Viatris, and Nordmark; serves on the advisory board for Zena, and is president of UEG (United European Gastroenterology). DY has received research funding from Siemens Healthineers, honoraria from Astellas Pharma, speaker fees from Bayer, a travel grant from the Multidisciplinary Digital Publishing Institute, and serves on the advisory boards for Hanarth, European Institute for Biomedical Imaging Research, and ICAI lab. GL holds stock options at Aiosyn. HH has received research funding from Siemens Healthineers and Canon Medical Systems. All other authors declare no competing interests.

Comment in

Publication types